Levetiracetam for managing neurologic and psychiatric disorders

被引:49
作者
Farooq, Muhammad U. [1 ]
Bhatt, Archit
Majid, Arsnm
Gupta, Rishi
Khasnis, Atul
Kassab, Mounzer Y. [1 ]
机构
[1] Michigan State Univ, Dept Neurol & Ophthalmol, Div Cerebrovasc Disorders, E Lansing, MI 48824 USA
关键词
Anticonvulsants; Epilepsy; Levetiracetam; Mechanism of action; Mental disorders; Nervous system diseases; Toxicity; ANTIEPILEPTIC DRUG LEVETIRACETAM; LEVODOPA-INDUCED DYSKINESIA; SYNAPTIC VESICLE PROTEIN; PLACEBO-CONTROLLED TRIAL; OPEN-LABEL TRIAL; ADD-ON THERAPY; DOUBLE-BLIND; TARDIVE-DYSKINESIA; INTRAVENOUS-INFUSION; ADJUNCTIVE TREATMENT;
D O I
10.2146/ajhp070607
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose. The role of levetiracetam in different epileptic, nonepileptic, neurologic, and psychiatric disorders is discussed. Summary. Levetiracetam, an antiepileptic drug (AED), was first approved as an adjunctive therapy for the treatment of partial epilepsy in adults, It is currently being used in the treatment of multiple seizure disorders, including generalized tonic-clonic; absence; myoclonic, especially juvenile myoclonic; Lennox-Gastaut syndrome; and refractory epilepsy In children and adults, Data are emerging on possible uses of levetiracetam outside the realm of epilepsy because of its unique mechanisms of action. There is preliminary evidence about the efficacy of levetiracetam in the treatment of different psychiatric disorders, including anxiety, panic, stress, mood and bipolar, autism, and Tourette's syndrome. The most serious adverse effects associated with levetiracetam use are behavioral in nature and might be more common in patients with a history of psychiatric and neurobehavioral problems. Conclusion. Levetiracetam is an effective AED with potential benefits in other neurologic and psychiatric disorders. The benefit-risk ratio in an individual patient with a specific condition should be used to determine its optimal use. Levetiracetam's use in nonepileptic conditions is not recommended until more data become available from larger trials.
引用
收藏
页码:541 / 561
页数:21
相关论文
共 109 条
[1]   A study of tremor in multiple sclerosis [J].
Alusi, SH ;
Worthington, J ;
Glickman, S ;
Bain, PG .
BRAIN, 2001, 124 :720-730
[2]   Incidence and predictors of seizures in patients with Alzheimer's disease [J].
Amatniek, JC ;
Hauser, WA ;
DelCastillo-Castaneda, C ;
Jacobs, DM ;
Marder, K ;
Bell, K ;
Albert, M ;
Brandt, J ;
Stern, Y .
EPILEPSIA, 2006, 47 (05) :867-872
[3]   Use of anticonvulsants for treatment of neuropathic pain [J].
Backonja, MM .
NEUROLOGY, 2002, 59 (05) :S14-S17
[4]   A case of levetiracetam (Keppra®) poisoning with clinical and toxicokinetic data [J].
Barrueto, F ;
Williams, K ;
Howland, MA ;
Hoffman, RS ;
Nelson, LS .
JOURNAL OF TOXICOLOGY-CLINICAL TOXICOLOGY, 2002, 40 (07) :881-884
[5]   Levetiracetam monotherapy in Alzheimer patients with late-onset seizures: a prospective observational study [J].
Belcastro, V. ;
Costa, C. ;
Galletti, F. ;
Pisani, F. ;
Calabresi, P. ;
Parnetti, L. .
EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 (10) :1176-1178
[6]   Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: A multicenter, double-blind, responder-selected study evaluating monotherapy [J].
Ben-Menachem, E ;
Falter, T .
EPILEPSIA, 2000, 41 (10) :1276-1283
[7]   Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy [J].
Berkovic, S. F. ;
Knowlton, R. C. ;
Leroy, R. F. ;
Schiemann, J. ;
Falter, U. .
NEUROLOGY, 2007, 69 (18) :1751-1760
[8]   Levetiracetam in bipolar spectrum disorders: first evidence of efficacy in an open, add- on study [J].
Bersani, G .
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2004, 19 (05) :355-356
[9]   A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy [J].
Betts, T ;
Waegemans, T ;
Crawford, P .
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2000, 9 (02) :80-87
[10]   Levedracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque [J].
Bezard, E ;
Hill, MP ;
Crossman, AR ;
Brotchie, JM ;
Michel, A ;
Grimée, R ;
Klitgaard, H .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 485 (1-3) :159-164